**University of Oklahoma Health Sciences Center**

**Regularly Scheduled Series**

**Cardiovascular Grand Rounds**

**Course No. 23D31**

**Thursday, December 1, 2022**

**7:15 am – 8:00 am**

**Join Zoom Meeting**

[**https://zoom.us/j/94231171000?pwd=M05MaVZ5MGxPNlJoQjduSUovSmVDZz09**](https://zoom.us/j/94231171000?pwd=M05MaVZ5MGxPNlJoQjduSUovSmVDZz09)

**Meeting ID: 942 3117 1000**

**Passcode: 12345678**

**Paxlovid in Patients with Cardiovascular Disease**

**Presented by**

  

**Sarju Ganatra, MD, FACC**

Vice Chair, Department of Medicine

Director, Cardio-Oncology Program

Landsman Heart & Vascular Center

Co-Director, Cardiac MRI Program

Assistant Professor

Tufts University School of Medicine

**Professional Practice Gaps:** Paxlovid interactions with cardiovascular medications are not well understood. Strategies to avoid harmful interactions are not well defined. Many cardiovascular professionals encountering patients who are on cardiovascular medications and Paxlovid may be unaware of these interactions.

**Learning Objectives:**  Upon completion of this session, participants will improve their competence and performance by being able to:

1. Describe the utility of Paxlovid in patients with cardiovascular disease.
2. Recognize potential interactions of Paxlovid with cardiovascular medications.
3. Apply individual and system-level interventions to avoid harmful drug-drug interactions.

**Accreditation Statement:** The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of .75 *AMA PRA Category 1 Credit™.*  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**ANCC (American Nurses Credentialing Center) Accreditation Statement:**

OU Medicine, Inc. is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

.75 CNE contact hours will be awarded for meeting the following criteria: 90% attendance of conference, completion and submission of evaluation form.

This educational activity does not include any content that relates to the products and/or services of a commercial interest that would create a conflict of interest.

**Mitigation Statement:** The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

**University of Oklahoma Equal Opportunity / Non‐Discrimination Statement:** The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at [link.ou.edu/reportingform](file:///%5C%5CDCH-COMD1%5Cdo%5Cocpd%5C22D%20RSS%20FY%202021-2022%5C22d%20Resources%5Clink.ou.edu%5Creportingform).

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit [www.ou.edu/eoo](http://www.ou.edu/eoo).

**Accommodation Statement:** For accommodations, please contact Debi Green @ debi-green@ouhsc.edu or Pam Tomey @ pam-tomey@ouhsc.edu.

**Disclaimer Statement:** Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

**Policy on Planner and Presenter Disclosure:** It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

**Acknowledgement of Commercial and In-Kind Support:** **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity.  An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

**This activity received no commercial or in-kind support.**

 **Disclosure & Mitigation Report**

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities.  We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

|  |  |
| --- | --- |
|  |  |
| **Role(s)** | **First Name** | **Last Name** | **Ineligible Company** | **Nature of the Financial Relationship**  |
| Planning Committee | Carol L. | Davenport, MSN, RN-BC, NPD-BC | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Course Contact | Candice | Edwards | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Course Contact | Debi L. | Green | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Planning Member/Moderator | Dwight W. | Reynolds, MD, FACC, FHRS, FAHA | Medtronic, Inc. | Honorarium, Research Support, Consultant, Research Studies |
| **Planner:** The conflict was resolved by Dr. Reynolds agreeing to recuse himself from planning content in the conflicted area.**Moderator:** the conflict was resolved by Dr. Reynolds agreeing to limit his role to the introduction of presenters, fielding questions, and moderating the flow of discussion between participants and presenters. |
| Course Director/Speaker | C.A. | Sivaram, MD | I have no financial relationships or affiliations with ineligible companies to disclose. |
| Presenter | Sarju | Ganatra MD, FACC | I have no financial relationships or affiliations with ineligible companies to disclose. |